Duoback Faces Delisting Review After Submitting Improvement Plan
Duoback submitted an improvement plan and faces a delisting review.
Related stories
Nasdaq to Delist Glucotrack After Listing-Rule Exception Failure
Nasdaq notified Glucotrack on October 28 that its securities would be delisted after the closing bid price fell to $0.87 on October 14, failing the terms of an exception to Nasdaq
M impact | REGULATION | Oct 29, 2026, 09:05 PM UTC
Propanc Biopharma Receives Nasdaq Delisting Notice
Nasdaq said Propanc Biopharma failed to meet the $1.00 minimum bid price requirement and is ineligible for a standard compliance period following a recent reverse stock split.
M impact | REGULATION | Oct 29, 2026, 09:03 PM UTC
Nasdaq Notifies Charming Medical of Potential Delisting Nov. 9
Nasdaq says Charming Medical will be delisted on November 9, 2026, unless the company appeals.
M impact | REGULATION | Oct 29, 2026, 08:54 PM UTC
US Promises Tariff Relief in Talks With Audi Over Georgia Plant, Sources Say
M impact | REGULATION | Oct 29, 2026, 08:38 PM UTC
Greek PM Reaffirms Support for Sanctions on Russia
M impact | REGULATION | Oct 29, 2026, 08:36 PM UTC
EU Patent Court Invalidates Enanta Patent in Pfizer Dispute
The EU Unified Patent Court invalidated an Enanta patent in its dispute with Pfizer over Paxlovid.
M impact | REGULATION | Oct 29, 2026, 08:24 PM UTC